Cuprior (trientine)
- Region
- 🇪🇺 EU
- Active substance
- trientine
- Company
- Orphalan
- Status
- Authorised
- Therapeutic area
- Hepatolenticular Degeneration
- CHMP opinion
- Fri 21 Apr 2017
- EU approval
- Tue 05 Sep 2017
- Application
- EMEA/H/C/004005
- ATC
- A16AX
- Official record
- www.ema.europa.eu
Indication
Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Cufence Authorised · Univar Solutions BV
Follow Cuprior
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.